Biocon Ltd

Biocon Other Announcement

Biocon Ltd filed its quarterly shareholding pattern as of June 30, 2026. The filing details holdings across promoter, institutional, and public categories.

Biocon Regulatory Approval

Biocon received EMA approval for a new insulin fill finish line in Malaysia. Supplies to the European market are expected to commence from Q2FY27.

Biocon Annual General Meeting

Biocon Limited convened its 48th AGM for August 6, 2026. Key agenda items include a 10% dividend declaration and adoption of a new long-term incentive plan.

Biocon Annual Report

Biocon Limited has released its Integrated Annual Report for FY 2025-26. The company's 48th Annual General Meeting is scheduled for August 06, 2026.

Biocon Capital Structure Change

Mylan Inc. sold 9,19,67,019 equity shares of Biocon Limited, representing a 5.64% stake. The transaction was executed via an open market sale.

Biocon Business Update

Biocon announced the publication of Phase III clinical data supporting the effectiveness of its biosimilar Yesafili™. The data reinforces clinical equivalence ahead of its US launch.

Biocon Capital Structure Change

Biocon allotted 8.78 million equity shares via preferential issue at Rs. 376.41 per share. The Rs. 330.73 Crore fund-raise increased paid-up capital.

Value

₹330.7 Cr

Biocon Merger & Restructuring Worth ₹330.7 Cr

Biocon Limited acquired remaining stakes in Biocon Biologics via a Rs. 330.73 Crore share swap. BBL is now a wholly-owned subsidiary after 87.86 lakh shares were allotted.

Value

₹330.7 Cr

Biocon Announces New Order Win

Biocon’s subsidiary will supply insulin to Duopharma Biotech under Malaysian MoH contracts worth over MYR 225 million. The three‑year and two‑year deals expand Biocon’s presence in Malaysia’s diabetes market.

Biocon Announces New Order Win

Biocon will supply insulin to Duopharma under contracts worth over MYR 225 million. The partnership strengthens its diabetes care footprint in Malaysia.

Biocon Acquisition Worth ₹5.48 Cr

Biocon invested Rs.5.48 Crore for a 37.77% stake in Ampin C&I Power Twelve, a solar SPV. This supports its renewable energy goals and reduces carbon footprint.

Value

₹5.48 Cr

Biocon Annual General Meeting

Biocon Limited announced the successful passage of several postal ballot resolutions. Key approvals include executive appointments, remuneration revisions, and a preferential issuance of equity shares.

Biocon Earnings Call: Key Takeaways

Biocon's June 2026 presentation highlights its transformation into an integrated biopharma leader following the Viatris acquisition. FY26 revenue reached $1,924M (₹16,927 Cr) with a 22% EBITDA margin.

Biocon Annual General Meeting

Biocon Limited has initiated a postal ballot for shareholder approval of a preferential equity share issuance. This corporate action seeks authorization for consideration other than cash.

Biocon Annual General Meeting

Biocon issued a corrigendum to its May 07 postal ballot notice regarding a ₹330.73 Crore preferential issue. It revises floor price, issue price, and allotment details.

Value

₹330.7 Cr

Biocon Earnings Call: Key Takeaways

Biocon Q4 FY26 reported 10% YoY revenue growth (ex-lenalidomide) with integration of biosimilars/generics complete. Focus shifts to execution and deleveraging.

Biocon Regulatory Approval

Biocon Pharma received Health Canada approval for Micafungin for Injection, USP. This milestone strengthens the company's integrated biosimilars and generics portfolio in Canada.

Biocon Annual General Meeting

Biocon Limited issued a postal ballot notice for multiple resolutions, including a ₹330.73 Crore preferential share issuance. Shareholders will vote electronically between May and June 2026.

Value

₹330.7 Cr

Biocon Earnings Call: Key Takeaways

Biocon Q3FY26 reports 9% operating revenue growth at Rs 4,173 Cr and 475% increase in Net Profit to Rs 144 Cr, driven by Biosimilars and Generics momentum.

Biocon Management Change

Biocon Limited announced a significant leadership restructuring, appointing several independent directors and senior management personnel. The board additions include global pharmaceutical and technology leaders.

Biocon Dividend

Biocon Limited recommended a final dividend of Rs. 0.1 per equity share for FY26. The record date is set for July 3, 2026.

Biocon Merger & Restructuring Worth ₹473.4 Cr

Biocon Limited will acquire 1.06 crore equity shares in Biocon Biologics via CCD conversion worth ₹473.40 Crore. The move aims to simplify its corporate structure.

Value

₹473.4 Cr

Biocon Acquisition Worth ₹330.7 Cr

Biocon will acquire a minority stake in Biocon Biologics for ₹330.73 Crore via share-swap. The deal consolidates BBL as a wholly owned subsidiary by June 2026.

Value

₹330.7 Cr

Execution

30/06/2026

Biocon Earnings Call: Key Takeaways

Biocon reported FY26 revenue of ₹16,927 Cr (+13% YoY adjusted). Transitioning from investment phase to execution, focusing on margin expansion and deleveraging across Biosimilars, Generics, and CRDMO.

Biocon Fund Raise of ₹8,650 Cr

Biocon Limited released Monitoring Agency Reports confirming zero deviation in utilizing ₹8,650 Crore raised via QIPs. The Audit Committee reviewed these reports on May 07, 2026.

Value

₹8,650 Cr

Biocon Results Update

Biocon Ltd reported Q4FY26 total income of ₹4,569 Crore and EBITDA of ₹1,073 Crore. Performance was driven by biosimilars and generics growth amid business integration.

Biocon Q4 FY26 Results: Net Profit ₹51 Cr, Up 140.6% YoY

Biocon Ltd reported revenue from operations of ₹604.7 Cr (-6.1% YoY) and net profit of ₹51 Cr (+140.6% YoY) for Q4 FY26.

Key figure

Net profit ₹51 Cr · +140.6% YoY

Biocon Financial Results

Biocon Limited reported its audited financial results for the year ended March 31, 2026. The board also recommended a final dividend of Rs. 0.50 per share.

Biocon Price Movement Clarification

Biocon Ltd clarified to exchanges that Ms. Kiran Mazumdar-Shaw remains Executive Chairperson and is not stepping down. The company denied reports of impending management or succession changes following media speculation and stock price movement on May 06, 2026. Management reiterated that all material information is disclosed per SEBI regulations.

Biocon Board Meeting Date

Biocon Limited has scheduled a board meeting for May 7, 2026, to consider a proposal for fundraising via a preferential issue. The trading window for the company's securities remains closed from April 1, 2026, until May 9, 2026, as per insider trading regulations.